Comparative Pharmacology
Head-to-head clinical analysis: LETERMOVIR versus VEKLURY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LETERMOVIR versus VEKLURY.
LETERMOVIR vs VEKLURY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Letermovir is an antiviral agent that inhibits the human cytomegalovirus (CMV) terminase complex, specifically the pUL56 subunit, thereby preventing viral DNA processing and packaging.
Remdesivir is a nucleotide analog prodrug that, after intracellular metabolism, incorporates into nascent viral RNA chains causing synthesis termination and inhibition of RNA-dependent RNA polymerase (RdRp). It targets the SARS-CoV-2 RdRp with selectivity over human RNA polymerases.
480 mg orally once daily (two 240 mg tablets).
200 mg IV on Day 1, then 100 mg IV once daily for 5 to 10 days.
None Documented
None Documented
The terminal elimination half-life is approximately 12 hours (range 10–18 hours) in healthy subjects, allowing once-daily dosing.
Clinical Note
moderateLetermovir + Teriflunomide
"The serum concentration of Teriflunomide can be increased when it is combined with Letermovir."
Clinical Note
moderateLetermovir + Haloperidol
"The metabolism of Haloperidol can be decreased when combined with Letermovir."
Clinical Note
moderateLetermovir + Clotrimazole
"The metabolism of Clotrimazole can be decreased when combined with Letermovir."
Clinical Note
moderateLetermovir + Dronedarone
Remdesivir: ~1 hour (parent); GS-441524: ~27 hours (terminal). Context: GS-441524 accumulation may occur with daily dosing.
Letermovir is primarily eliminated via biliary/fecal excretion (approximately 93% of the dose recovered in feces, with <2% as unchanged drug) and renal excretion accounts for <7% (mostly as metabolites, <1% unchanged).
Renal: 10% unchanged remdesivir; 49% as metabolite GS-441524; 18% as other metabolites. Fecal: 47.5% as metabolites. Biliary: minor.
Category C
Category C
Antiviral
Antiviral
"The metabolism of Dronedarone can be decreased when combined with Letermovir."